CN112869871B - Ablation device, control method, device, system and storage medium thereof - Google Patents
Ablation device, control method, device, system and storage medium thereof Download PDFInfo
- Publication number
- CN112869871B CN112869871B CN202110031437.1A CN202110031437A CN112869871B CN 112869871 B CN112869871 B CN 112869871B CN 202110031437 A CN202110031437 A CN 202110031437A CN 112869871 B CN112869871 B CN 112869871B
- Authority
- CN
- China
- Prior art keywords
- electrode needle
- medicament
- ablation
- release
- pulse sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00107—Coatings on the energy applicator
- A61B2018/00154—Coatings on the energy applicator containing and delivering drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
- A61B2018/00613—Irreversible electroporation
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plasma & Fusion (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Electrotherapy Devices (AREA)
Abstract
The embodiment of the application provides an ablation device, a control method, a control device, a control system and a storage medium of the ablation device. The ablation device includes: the electrode needle is used for extending into target tissue; the pulse generating device is electrically connected with the electrode needle; the controller is respectively in communication connection with the electrode needle and the pulse generating device and is used for controlling the electrode needle to release the medicament to at least part of target tissues and controlling the pulse generating device to output an electric pulse sequence to the electrode needle; the sequence of electrical pulses includes a first sequence of pulses for ablating at least a portion of the target tissue surrounding the electrode needle. The embodiment of the application realizes the combination of electric ablation and medicine ablation, and improves the ablation effect; and the electrical ablation causes electroporation of the extracellular membrane of the target tissue, which allows the agent to more easily enter the cells of the target tissue, greatly improving the ablation effect.
Description
Technical Field
The application relates to the technical field of medical equipment, in particular to an ablation device and a control method, device, system and storage medium thereof.
Background
The electroporation technology mainly adopted by the electrical ablation is that electric field pulses are sent to focus cells, ions inside and outside the cells move and are gathered on two sides of a cell outer membrane, so that transmembrane potential is changed rapidly, the cell outer membrane is subjected to electroporation, the balance inside and outside the cells is broken, and the ablation purpose is achieved.
The existing electric ablation device only has the function of electric ablation, and the ablation effect is difficult to improve.
Disclosure of Invention
The application aims at the defects of the existing mode and provides an ablation device, a control method, a device, a system and a storage medium thereof, which are used for solving the technical problem that the ablation effect of an electric ablation device is difficult to improve in the prior art.
In a first aspect, embodiments of the present application provide an ablation device comprising:
the electrode needle is used for extending into target tissue;
the pulse generating device is electrically connected with the electrode needle;
the controller is respectively in communication connection with the electrode needle and the pulse generating device and is used for controlling the electrode needle to release the medicament to at least part of target tissues and controlling the pulse generating device to output an electric pulse sequence to the electrode needle; the sequence of electrical pulses includes a first sequence of pulses for ablating at least a portion of the target tissue surrounding the electrode needle.
Optionally, the electrode needle has a medicament chamber for connection to a medicament source, and the peripheral wall of the electrode needle has a medicament release hole communicating with the medicament chamber.
In a second aspect, the present application provides a control method for an ablation apparatus provided in the first aspect, including:
controlling a pulse generating device in the ablation device to output a first pulse sequence to the electrode needle so as to ablate at least part of target tissue around the electrode needle;
the electrode needle is controlled to release the medicament to at least a portion of the target tissue at a first design time.
Optionally, controlling the electrode needle to release the agent to at least a portion of the target tissue at a first design time comprises:
controlling the electrode needle to release the medicament after determining that the first pulse sequence is started to be output through the electrode needle;
after it is determined that the entire medicament is discharged through the electrode needle, the pulse generating means is controlled to stop outputting the first pulse train.
Optionally, after determining that the first pulse sequence is output through the electrode needle, controlling the electrode needle to release the medicament comprises:
after determining that at least one electric pulse in the first pulse sequence is output through the electrode needle, controlling the electrode needle to perform at least one sub-medicament release process in at least two sub-medicament release processes;
and after determining that at least one other electric pulse in the first pulse sequence is output through the electrode needle, controlling the electrode needle to perform at least one other sub-release medicament process in the at least two sub-release medicament processes.
Optionally, controlling the electrode needle to release the agent to at least a portion of the target tissue at a first design time comprises:
controlling the electrode needle to release the medicament after determining that the first pulse sequence is started to be output through the electrode needle;
and controlling the electrode needle to stop releasing the medicament after determining that the electrode needle stops outputting the first pulse sequence.
Optionally, after determining that the first pulse sequence is output through the electrode needle, controlling the electrode needle to release the medicament comprises:
and after determining that at least one electric pulse in the first pulse sequence is output through the electrode needle, controlling the electrode needle to perform at least one sub-medicament release process in at least two sub-medicament release processes.
Optionally, after determining that the electrode needle stops outputting the first pulse sequence, controlling the electrode needle to stop releasing the medicament comprises:
and after the electrode needle is determined to stop outputting the first pulse sequence, controlling the electrode needle to perform at least another sub-medicament release process in the at least two sub-medicament release processes.
Optionally, controlling the electrode needle to release the agent to at least a portion of the target tissue at a first design time comprises:
and controlling the electrode needle to release the medicament when the first pulse sequence is determined to be completely output through the electrode needle and the second design time is separated.
In a third aspect, embodiments of the present application provide a control device for an ablation device, including:
the electric pulse control module is used for controlling a pulse generating device in the ablation device to output a first pulse sequence to the electrode needle so as to ablate at least part of target tissues around the electrode needle;
and the medicament releasing module is used for controlling the electrode needle to release the medicament to at least part of the target tissue at the first design time.
Optionally, the medicament releasing module is further used for controlling the electrode needle to release the medicament after determining that the first pulse sequence is output through the electrode needle;
the electric pulse control module is also used for controlling the pulse generating device to stop outputting the first pulse sequence after all the medicaments are determined to be released through the electrode needle.
Optionally, the medicament release module is further configured to control the electrode needle to release the medicament after determining that the first pulse sequence is output through the electrode needle; and controlling the electrode needle to stop releasing the medicament after determining that the electrode needle stops outputting the first pulse sequence.
Optionally, the medicament release module is further configured to control the electrode needle to release the medicament when it is determined that the entire first pulse sequence is output through the electrode needle and the second design time has elapsed.
In a fourth aspect, embodiments of the present application provide a computer-readable storage medium storing a computer program, which when executed by a processor, implements the method for controlling an ablation apparatus as provided in the second aspect.
In a fifth aspect, embodiments of the present application provide an ablation system, comprising: an ablation device as provided in the first aspect, and a host computer;
the upper computer is in communication connection with a controller in the ablation device.
The beneficial technical effects brought by the ablation device and the ablation system provided by the embodiment of the application comprise: the controller can control the pulse generating device to output a first pulse sequence to the electrode needle, so that the electrode needle extending into target tissue can perform electric ablation on the surrounding target tissue; the controller can also control the electrode needle to release medicament to at least part of target tissues, so that the electrode needle extending into the target tissues can perform medicament ablation on the surrounding target tissues, namely the combination of electrical ablation and medicament ablation is realized, and the ablation effect is improved; and the electrical ablation causes the cell adventitia of the target tissue to form electroporation, which makes the agent more easily enter the cells of the target tissue, and can greatly improve the ablation effect.
The control method, the control device and the computer-readable storage medium of the ablation device provided by the embodiment of the application have the beneficial technical effects that: the first pulse sequence can be output to the electrode needle by controlling the pulse generating device, so that the electrode needle extending into the target tissue can perform electric ablation on the surrounding target tissue; the electrode needle extending into the target tissue can perform drug ablation on the surrounding target tissue by controlling the electrode needle to release a medicament to at least part of the target tissue, namely the electrical ablation and the drug ablation are combined, so that the ablation effect is improved; and the electrical ablation causes electroporation of the extracellular membrane of the target tissue, which allows the agent to more easily enter the cells of the target tissue, greatly improving the ablation effect.
Additional aspects and advantages of the present application will be set forth in part in the description which follows and, in part, will be obvious from the description, or may be learned by practice of the present application.
Drawings
The foregoing and/or additional aspects and advantages of the present application will become apparent and readily appreciated from the following description of the embodiments, taken in conjunction with the accompanying drawings of which:
fig. 1 is a schematic diagram of a frame of an ablation device according to an embodiment of the present application;
fig. 2 is a block diagram of an ablation system according to an embodiment of the present disclosure;
fig. 3 is a schematic flowchart of a control method of an ablation device according to an embodiment of the present application;
fig. 4 is a schematic flowchart of another control method for an ablation device according to an embodiment of the present application;
fig. 5 is a schematic flow chart illustrating a process of controlling the electrode needle to release the medicament after determining that the first pulse sequence is output through the electrode needle in another control method of the ablation device provided by the embodiment of the application based on the foregoing embodiment;
fig. 6 is a schematic flowchart of a control method of an ablation device according to an embodiment of the present application;
fig. 7 is a schematic flowchart of a control method of an ablation device according to an embodiment of the present application based on the foregoing embodiment;
fig. 8 is a schematic view of a control device frame of an ablation device according to an embodiment of the present application;
fig. 9 is a schematic view illustrating an ablation state of an electrode needle in an ablation apparatus according to an embodiment of the present application.
In the figure:
100-an ablation system; 110-an ablation device; 111-electrode needle; 112-pulse generating means; 113-a controller; 120-an upper computer;
200-a control device of the ablation device; 210-an electric pulse control module; 220-a medicament release module;
310-target tissue; 320-ablation zone.
Detailed Description
Reference will now be made in detail to the present application, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to the same or similar parts or parts having the same or similar functions throughout. In addition, if a detailed description of the known art is not necessary for illustrating the features of the present application, it is omitted. The embodiments described below with reference to the drawings are exemplary only for the purpose of explaining the present application and are not to be construed as limiting the present application.
It will be understood by those within the art that, unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the prior art and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.
As used herein, the singular forms "a", "an", "the" and "the" are intended to include the plural forms as well, unless the context clearly indicates otherwise. It will be further understood that the terms "comprises" and/or "comprising," when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. It will be understood that when an element is referred to as being "connected" or "coupled" to another element, it can be directly connected or coupled to the other element or intervening elements may also be present. Further, "connected" or "coupled" as used herein may include wirelessly connected or wirelessly coupled. As used herein, the term "and/or" includes all or any element and all combinations of one or more of the associated listed items.
The inventor of the application researches and discovers that the electroporation technology mainly adopted by the electric ablation is that ions inside and outside cells move and gather on two sides of an outer cell membrane by sending electric field pulses to focus cells to cause the rapid change of transmembrane potential, the outer cell membrane is subjected to electroporation to break the balance between the inside and the outside of the cells, and then the treatment purpose is achieved. However, the existing electric ablation device only has an electric ablation function, and the function is single, so that the ablation effect is difficult to improve.
The application provides an ablation device, a control method, a control device, a control system and a storage medium thereof, which aim to solve the technical problems in the prior art.
The following describes the technical solutions of the present application and how to solve the above technical problems with specific embodiments.
The embodiment of the application provides an ablation device, the structural schematic diagram of which is shown in fig. 1, and the ablation device comprises: an electrode needle 111, a pulse generating device 112 and a controller 113.
The electrode needle 111 is used to extend into the target tissue 310.
The pulse generating device 112 is electrically connected to the electrode needle 111.
The controller 113 is respectively connected with the electrode needle 111 and the pulse generating device 112 in a communication manner, and is used for controlling the electrode needle 111 to release the medicament to at least part of the target tissue 310 and controlling the pulse generating device 112 to output an electric pulse sequence to the electrode needle 111; the sequence of electrical pulses includes a first sequence of pulses for ablating at least a portion of the target tissue 310 around the electrode needle 111.
In this embodiment, the controller 113 may control the pulse generating device 112 to output a first pulse sequence to the electrode needle 111, so that the electrode needle 111 extending into the target tissue 310 may perform electrical ablation on at least a portion of the surrounding target tissue 310.
The controller 113 may further control the electrode needle 111 to release the medicament to at least a portion of the target tissue 310, so that the electrode needle 111 extending into the target tissue 310 may perform drug ablation on at least a portion of the surrounding target tissue 310, that is, the electrical ablation and the drug ablation are combined to improve the ablation effect.
And the electrical ablation causes the adventitia of the target tissue 310 to form electroporation, which allows the agent to more easily enter the cells of the target tissue 310, which can greatly improve the ablation effect.
Specifically, at the time of ablation operation, as shown in fig. 9, the electrode needle 111 is extended into the ablation region 320 of the target tissue 310 at the lesion.
In some possible embodiments, the electrode needle 111 has a medicine chamber for connecting with a medicine source, and the peripheral wall of the electrode needle 111 has a medicine release hole communicating with the medicine chamber.
In this embodiment, the electrode needle 111 may be a hollow cylindrical structure, the hollow portion is a medicament cavity, one end of the electrode needle may be connected to an external medicament source through a pipeline, and the medicament source may be a medicament storage tank.
Alternatively, one end of the electrode needle 111, or a pipe connected to one end of the electrode needle 111, may be provided with a control valve, which is communicatively connected to the controller 113 to control the electrode needle 111 to release or close the medicament delivered from the medicament source according to an open/close command of the controller 113.
Alternatively, the other end of the electrode needle 111 may be an opening to facilitate the release of the medicine.
Alternatively, the other end of the electrode needle 111 may be closed, and the entire medicine is discharged through the medicine discharge hole of the circumferential wall of the electrode needle 111.
In some possible embodiments, the ablation device 110 may further include a memory. The controller 113 and the memory are electrically connected, such as by a bus. Alternatively, the controller 113 may be a CPU (Central Processing Unit), a general-purpose Processor, a DSP (Digital Signal Processor), an ASIC (Application Specific Integrated Circuit), an FPGA (Field-Programmable Gate Array) or other Programmable logic device, a transistor logic device, a hardware component, or any combination thereof. Which may implement or execute the various illustrative logical blocks, modules, and circuits described in connection with the disclosure herein. The controller 113 may also be a combination of implementing computing functions, e.g., comprising one or more microprocessors, DSPs and microprocessors, and the like.
Alternatively, the bus may include a path that carries information between the aforementioned components. The bus may be a PCI (Peripheral Component Interconnect) bus, an EISA (Extended Industry Standard Architecture) bus, or the like. The bus may be divided into an address bus, a data bus, a control bus, etc.
Alternatively, the Memory may be a ROM (Read-Only Memory) or other type of static storage device that can store static information and instructions, a RAM (random access Memory) or other type of dynamic storage device that can store information and instructions, an EEPROM (Electrically Erasable Programmable Read-Only Memory), a CD-ROM (Compact Disc Read-Only Memory) or other optical disk storage, optical disk storage (including Compact Disc, laser Disc, optical Disc, digital versatile Disc, blu-ray Disc, etc.), a magnetic disk storage medium or other magnetic storage device, or any other medium that can be used to carry or store desired program code in the form of instructions or data structures and that can be accessed by a computer, but is not limited to such.
In some possible embodiments, the ablation device 110 may further include a monitoring unit. The monitoring unit can be used for monitoring the current and/or voltage parameters of the electrode needle 111 and monitoring the drug releasing state of the electrode needle 111, and the controller 113 determines the working state of the electrode needle 111 through the current and/or voltage parameters of the electrode needle 111 and the drug releasing state of the electrode needle, which are obtained by the monitoring unit. For example, if the current and/or voltage parameters of the electrode needle 111 obtained by the monitoring unit are consistent with the current and/or voltage of the electrode needle 111 when the electrode needle is unloaded (not connected to a load), it is determined that the electrode needle 111 has currently completed outputting the electrical pulse sequence; if the monitoring unit obtains that there is no medicament flow at the electrode needle 111, it is determined that the electrode needle 111 has stopped releasing medicament currently.
In some possible embodiments, the ablation device 110 may also include a transceiver. The transceiver may be used for reception and transmission of signals. The transceiver may allow the controller 113 of the ablation device 110 to wirelessly or wiredly communicate with other devices to exchange data, for example, when the controller 113 receives an ablation stop command or a drug administration stop command inputted by a user through the transceiver, the controller 113 is triggered to control the pulse generating device 112 to stop outputting the first pulse sequence or control the electrode needle 111 to stop releasing the drug. It should be noted that the transceiver is not limited to one in practical application.
In some possible embodiments, the ablation device 110 may further include an input unit. The input unit may be used to receive input numeric, character, image and/or sound information or to generate key signal inputs related to user settings and function control of the controller 113. The input unit may include, but is not limited to, one or more of a touch screen, a physical keyboard, function keys (such as volume control keys, switch keys, etc.), a trackball, a mouse, a joystick, a camera, a microphone, and the like.
In some possible embodiments, the ablation device 110 may further include an output unit. The output unit may be used to output or present information processed by the controller 113. The output unit may include, but is not limited to, one or more of a display device, a speaker, a vibration device, and the like.
It will be appreciated by those skilled in the art that the controller 113 of the ablation device 110 provided in the embodiments of the present application may be specifically designed and manufactured for the desired purpose, or may comprise known equipment found in general purpose computers. These devices have stored within them computer programs that are selectively activated or reconfigured. Such a computer program may be stored in a device (e.g., computer) readable medium or in any type of medium suitable for storing electronic instructions and respectively coupled to a bus.
Based on the same inventive concept, the present application provides a control method of an ablation apparatus based on the foregoing embodiments, the flow chart of the method is shown in fig. 3, and the control method includes, but is not limited to, steps S101 to S102:
s101: controlling a pulse generating device in the ablation device to output a first pulse sequence to the electrode needle to ablate at least a portion of the target tissue around the electrode needle.
Optionally, the controller 113 controls the pulse generating device 112 in the ablation device 110 to output a first pulse sequence to the electrode needle 111 to ablate at least part of the target tissue 310 around the electrode needle 111.
S102: the electrode needle is controlled to release the pharmaceutical agent to at least a portion of the target tissue at a first design time.
Optionally, the controller 113 controls the electrode needle 111 to release the medicament to at least a portion of the target tissue at a first design time.
In the present embodiment, a first pulse sequence can be outputted to the electrode needle 111 by controlling the pulse generating device 112, so that the electrode needle 111 extending into the target tissue 310 can perform electrical ablation on at least part of the surrounding target tissue 310; the electrode needle 111 can be controlled to release the medicament to at least part of the target tissue 310, so that the electrode needle 111 extending into the target tissue 310 can perform drug ablation on at least part of the surrounding target tissue 310, that is, the electrical ablation and the drug ablation are combined, and the ablation effect is improved; and the electrical ablation causes electroporation of the extracellular membrane of the target tissue 310, which allows the agent to more easily enter the cells of the target tissue, greatly enhancing the ablation effect.
The present embodiment provides another control method for an ablation apparatus based on the foregoing embodiments, the flowchart of the method is shown in fig. 4, and the control method includes, but is not limited to, the following steps S201 to S203:
s201: and controlling a pulse generating device in the ablation device to output a first pulse sequence to the electrode needle so as to ablate at least part of the target tissue around the electrode needle.
Optionally, the controller 113 controls the pulse generating device 112 in the ablation device 110 to output a first pulse sequence to the electrode needle 111 to ablate at least a portion of the target tissue around the electrode needle 111.
S202: and controlling the electrode needle to release the medicament after determining that the first pulse sequence is started to be output through the electrode needle.
Alternatively, after the controller 113 determines that the first pulse train is started to be output through the electrode needle 111, the controller 113 controls the electrode needle 111 to release the medicine.
S203: and controlling the pulse generating device to stop outputting the first pulse sequence after determining that all the medicament is released through the electrode needle.
Alternatively, after the controller 113 determines that the entire medicament is discharged through the electrode needle 111, the controller 113 controls the pulse generating device 112 to stop outputting the first pulse train.
In the present embodiment, the output of the electrode needle 111 of the first pulse sequence starts before the start point of the drug releasing process of the electrode needle 111, and the output of the electrode needle 111 of the first pulse sequence ends after the end point of the drug releasing process of the electrode needle 111. Therefore, the medicament can form the cells which enter target tissues through electroporation formed by the cell outer membrane to the maximum extent, the ratio of the medicament entering the cells is improved, and the ablation effect inside the cells is improved.
In some possible embodiments, as shown in fig. 5, after determining that the first pulse sequence is output through the electrode needle in the step S202, the electrode needle is controlled to release the medicament, including, but not limited to, the following steps S2021-S2022:
s2021: and after determining that at least one electric pulse in the first pulse sequence is output through the electrode needle, controlling the electrode needle to perform at least one sub-medicament release process in at least two sub-medicament release processes.
Alternatively, after the controller 113 determines that at least one electrical pulse of the first pulse train is output through the electrode needle 111, the controller 113 controls the electrode needle 111 to perform at least one sub-release dose schedule of the at least two sub-release dose schedules.
S2022: and after determining that at least one other electric pulse in the first pulse sequence is output through the electrode needle, controlling the electrode needle to perform at least one other sub-release medicament process in the at least two sub-release medicament processes.
Alternatively, after the controller 113 determines that at least another electrical pulse in the first pulse train is output through the electrode needle 111, the controller 113 controls the electrode needle 111 to perform at least another sub-release dose schedule of the at least two sub-release dose schedules.
In this embodiment, at least one sub-release agent process is located between two adjacent electric pulses in the first pulse sequence, which is beneficial to realize the alternation between each electric pulse in the first pulse sequence and each sub-release agent process in the release agent process, so that on one hand, the matching degree of electroporation and the sub-release agent process can be improved, that is, each time the agent is released, the outer cell membrane has effective electroporation, and the ratio of the agent entering the cell is improved; on the other hand, the working state of the electrode needle 111 is favorably spaced, the influence between the medicament and the first pulse sequence is reduced, the respective effectiveness of electric ablation and medicament ablation is ensured, and the ablation effect is further improved.
The embodiment of the present application provides yet another control method for an ablation apparatus based on the foregoing embodiment, the flowchart of the method is shown in fig. 6, and the control method includes, but is not limited to, the following steps S301 to S303:
s301: and controlling a pulse generating device in the ablation device to output a first pulse sequence to the electrode needle so as to ablate at least part of the target tissue around the electrode needle.
Optionally, the controller 113 controls the pulse generating device 112 in the ablation device 110 to output a first pulse sequence to the electrode needle 111 to ablate at least part of the target tissue around the electrode needle 111.
S302: and controlling the electrode needle to release the medicament after determining that the first pulse sequence is started to be output through the electrode needle.
Alternatively, after the controller 113 determines that the first pulse train is started to be output through the electrode needle 111, the controller 113 controls the electrode needle 111 to release the medical agent.
S303: and controlling the electrode needle to stop releasing the medicament after determining that the electrode needle stops outputting the first pulse sequence.
Alternatively, after the controller 113 determines that the electrode needle 111 stops outputting the first pulse sequence, the controller 113 controls the electrode needle 111 to stop releasing the medicine.
In this embodiment, the output of the electrode needle 111 of the first pulse sequence starts before the start point of the medicament releasing process of the electrode needle 111, and the output of the electrode needle 111 of the first pulse sequence ends before the end point of the medicament releasing process of the electrode needle 111. Thus, the outer cell membrane can form effective electroporation in the process of releasing the medicament so as to facilitate the medicament to enter cells of the target tissue. That is, the ratio of the agent entering the cell can be increased, the ablation effect inside the cell can be improved, the time for outputting the first pulse sequence by the electrode needle 111 can be shortened, and the energy consumption can be saved.
In some possible embodiments, after determining that the first pulse sequence is output through the electrode needle, the controlling the electrode needle to release the medicament in step S302 includes: and after determining that at least one electric pulse in the first pulse sequence is output through the electrode needle, controlling the electrode needle to perform at least one sub-medicament release process in at least two sub-medicament release processes.
In this embodiment, at least one sub-release agent process is located between two adjacent electric pulses in the first pulse sequence, which is beneficial to realize the alternating operation of each electric pulse in the first pulse sequence and part of sub-release agent processes in the release agent process, so that on one hand, the matching degree of electroporation and part of sub-release agent processes can be improved, that is, each time the agent is released, the outer cell membrane has effective electroporation, and the proportion of the agent entering the cell is improved; on the other hand, the working state of the electrode needle 111 is favorably spaced, the influence between the medicament and the first pulse sequence is reduced, the respective effectiveness of electric ablation and medicament ablation is ensured, and the ablation effect is further improved.
In some possible embodiments, controlling the electrode needle to stop releasing the medicament after determining that the electrode needle stops outputting the first pulse sequence in step S303 includes: and after the electrode needle is determined to stop outputting the first pulse sequence, controlling the electrode needle to perform at least another sub-medicament release process in the at least two sub-medicament release processes.
In this embodiment, at least one sub-release agent course is located after all electrical pulses in the first pulse train, which may facilitate a continuous administration after electrical ablation. Specifically, irreversible electroporation is formed in the target tissue 310 under the ablation, and after the sustained drug delivery, the drug can continue to enter the cells through the electroporation, so that the time of outputting the first pulse sequence by the electrode needle 111 can be shortened while the curative effect of the drug ablation can be ensured, and the energy consumption can be saved.
The embodiment of the present application provides a further control method of an ablation apparatus based on the foregoing embodiment, a flowchart of the method is shown in fig. 7, and the control method includes, but is not limited to, the following steps S401 to S402:
s401: and controlling a pulse generating device in the ablation device to output a first pulse sequence to the electrode needle so as to ablate at least part of the target tissue around the electrode needle.
Optionally, the controller 113 controls the pulse generating device 112 in the ablation device 110 to output a first pulse sequence to the electrode needle 111 to ablate at least part of the target tissue around the electrode needle 111.
S402: and controlling the electrode needle to release the medicament when the first pulse sequence is determined to be completely output through the electrode needle and the second design time is separated.
Alternatively, when the controller 113 determines that the entire first pulse train is output through the electrode needle 111 and that the second design time has elapsed, the controller 113 controls the electrode needle 111 to release the medical agent.
In this embodiment, the output of the first pulse train of the electrode needle 111 starts before the start of the medicament releasing process of the electrode needle 111, and the output of the first pulse train of the electrode needle 111 ends after the end of the medicament releasing process of the electrode needle 111. Therefore, the medicament can form the cells which enter target tissues through electroporation formed by the cell outer membrane to the maximum extent, the ratio of the medicament entering the cells is improved, and the ablation effect inside the cells is improved.
Based on the same inventive concept, the control device 200 of the ablation device provided in the embodiments of the present application, as shown in fig. 8, includes: an electrical pulse control module 210 and a medicament release module 220.
The electric pulse control module 210 is used for controlling a pulse generating device in the ablation device to output a first pulse sequence to the electrode needle so as to ablate at least part of target tissue around the electrode needle.
The drug release module 220 is used for controlling the electrode needle to release the drug to at least part of the target tissue at the first design time.
In this embodiment, the electric pulse control module 210 may output a first pulse sequence to the electrode needle 111 by controlling the pulse generating device 112, so that the electrode needle 111 extending into the target tissue 310 can perform electric ablation on at least a part of the surrounding target tissue 310.
The drug releasing module 220 can release the drug to at least part of the target tissue 310 by controlling the electrode needle 111, so that the electrode needle 111 extending into the target tissue 310 can perform drug ablation on at least part of the surrounding target tissue 310, that is, the electrical ablation and the drug ablation are combined, thereby improving the ablation effect.
And the electrical ablation causes electroporation of the extracellular membrane of the target tissue 310, which allows the agent to more easily enter the cells of the target tissue, greatly enhancing the ablation effect.
In some possible embodiments, the drug release module 220 is further configured to control the electrode needle to release the drug after determining that the first pulse sequence is started to be output through the electrode needle. The electric pulse control module 210 is further configured to control the pulse generating device to stop outputting the first pulse train after determining that all of the medicament is released through the electrode needle.
In this embodiment, the output of the first pulse train of the electrode needle 111 starts before the start of the medicament releasing process of the electrode needle 111, and the output of the first pulse train of the electrode needle 111 ends after the end of the medicament releasing process of the electrode needle 111. Therefore, the medicament can form the cells which enter target tissues through electroporation formed by the cell outer membrane to the maximum extent, the ratio of the medicament entering the cells is improved, and the ablation effect inside the cells is improved.
Optionally, the medicament release module 220 is configured to control the electrode needle to perform at least one sub-medicament release process of at least two sub-medicament release processes after determining that at least one electrical pulse in the first pulse sequence is output through the electrode needle; and controlling the electrode needle to perform at least another sub-release medicament process of the at least two sub-release medicament processes after determining that at least another electric pulse in the first pulse sequence is output through the electrode needle.
In this embodiment, the agent releasing module 220 enables at least one sub-agent releasing process to be located between two adjacent electric pulses in the first pulse sequence, which is beneficial to realize the alternation between each electric pulse in the first pulse sequence and each sub-agent releasing process in the agent releasing process, so that on one hand, the matching degree of electroporation and the sub-agent releasing process can be improved, that is, when the agent is released each time, the outer cell membrane has effective electroporation, and the ratio of the agent entering the cell is improved; on the other hand, the working state of the electrode needle 111 is favorably spaced, the influence between the medicament and the first pulse sequence is reduced, the respective effectiveness of electric ablation and medicament ablation is ensured, and the ablation effect is further improved.
In some possible embodiments, the drug release module 220 is further configured to control the electrode needle to release the drug after determining that the first pulse sequence is started to be output through the electrode needle; and controlling the electrode needle to stop releasing the medicament after determining that the electrode needle stops outputting the first pulse sequence.
In this embodiment, the output of the electrode needle 111 of the first pulse sequence starts before the start point of the medicament releasing process of the electrode needle 111, and the output of the electrode needle 111 of the first pulse sequence ends before the end point of the medicament releasing process of the electrode needle 111. Thus, the outer cell membrane can form effective electroporation in the process of releasing the medicament so as to facilitate the medicament to enter cells of the target tissue. That is, the time for outputting the first pulse train by the electrode needle 111 can be shortened while increasing the ratio of the agent entering the cell and the ablation effect inside the cell, thereby saving energy consumption.
Optionally, the medicament release module 220 is configured to control the electrode needle to perform at least one sub-release medicament process of the at least two sub-release medicament processes after determining that at least one electrical pulse of the first pulse sequence is output through the electrode needle.
In this embodiment, at least one sub-release agent process is located between two adjacent electric pulses in the first pulse sequence, which is beneficial to realize the alternating operation of each electric pulse in the first pulse sequence and part of sub-release agent processes in the release agent process, so that on one hand, the matching degree of electroporation and part of sub-release agent processes can be improved, that is, each time the agent is released, the outer cell membrane has effective electroporation, and the proportion of the agent entering the cell is improved; on the other hand, the working state of the electrode needle 111 is favorably spaced, the influence between the medicament and the first pulse sequence is reduced, the respective effectiveness of electric ablation and medicament ablation is ensured, and the ablation effect is further improved.
Optionally, the drug releasing module 220 is configured to control the electrode needle to perform at least another sub-release drug process of the at least two sub-release drug processes after determining that the electrode needle stops outputting the first pulse sequence.
In this embodiment, at least one sub-release agent course is located after all electrical pulses in the first pulse train, which may facilitate a continuous administration after electrical ablation. Specifically, irreversible electroporation is formed in the target tissue 310 under the action of ablation, and after continuous administration, the medicament can continue to enter cells through electroporation, so that the time of outputting the first pulse sequence by the electrode needle 111 can be shortened while the curative effect of drug ablation can be ensured, and the energy consumption can be saved.
In some possible embodiments, the drug release module 220 is further configured to control the electrode needle to release the drug when it is determined that the entire first pulse sequence is outputted through the electrode needle and the second design time has elapsed.
In this embodiment, the output of the first pulse train of the electrode needle 111 starts before the start of the medicament releasing process of the electrode needle 111, and the output of the first pulse train of the electrode needle 111 ends after the end of the medicament releasing process of the electrode needle 111. Therefore, the medicament can form cells which are electroporated into target tissues through the cell adventitia to the greatest extent, the ratio of the medicament entering the cells is improved, and the ablation effect inside the cells is improved.
Based on the same inventive concept, embodiments of the present application provide a computer-readable storage medium, which stores a computer program, and the computer program is executed by a processor to implement the control method of any one of the ablation devices as provided in the foregoing embodiments.
A computer-readable storage medium provided by an embodiment of the present application is suitable for various alternative embodiments of the control method of the ablation device. And will not be described in detail herein.
Those skilled in the art will appreciate that the computer-readable storage media provided by the embodiments can be any available media that can be accessed by the electronic device and includes both volatile and nonvolatile media, removable and non-removable media. The computer readable storage medium includes, but is not limited to, any type of disk including floppy disks, hard disks, optical disks, CD-ROMs, and magneto-optical disks, ROMs, RAMs, EPROMs (Erasable Programmable Read-Only memories), EEPROMs (Electrically Erasable Programmable Read-Only memories), flash memories, magnetic cards, or optical cards. That is, a computer-readable storage medium includes any medium that stores or transmits information in a form readable by a device (e.g., a computer).
Based on the same inventive concept, the present application provides an ablation system 100, as shown in fig. 2, including: an ablation device 110 as in any of the previous embodiments, and a host computer 120.
The host computer 120 is in communication with the controller 113 in the ablation device 110.
In this embodiment, the upper computer 120 may implement program update or data backup for the ablation device 110, and may also implement remote control for the ablation device 110, thereby facilitating function expansion of the ablation device 110.
Optionally, the host computer 120 is in communication connection with the controller 113 in the ablation device 110 through WIFI (WIreless FIdelity).
Optionally, the upper computer 120 is communicatively connected to the controller 113 in the ablation device 110 via a cloud.
By applying the embodiment of the application, at least the following beneficial effects can be realized:
1. the controller 113 of the ablation apparatus 110 may control the pulse generating apparatus 112 to output a first pulse sequence to the electrode needle 111 so that the electrode needle 111 extending into the target tissue 310 may perform electrical ablation on at least a portion of the surrounding target tissue 310; the controller 113 can also control the electrode needle 111 to release the medicament to at least part of the target tissue 310, so that the electrode needle 111 extending into the target tissue 310 can perform drug ablation on at least part of the surrounding target tissue 310, that is, the electrical ablation and the drug ablation are combined to improve the ablation effect; and the electrical ablation causes electroporation of the extracellular membrane of the target tissue 310, which allows the agent to more easily enter the cells of the target tissue 310, which may greatly improve the ablation effect.
2. Based on the control method of the ablation apparatus, a first pulse sequence can be output to the electrode needle 111 by controlling the pulse generating device 112, so that the electrode needle 111 extending into the target tissue 310 can perform electrical ablation on at least part of the surrounding target tissue 310; the electrode needle 111 can be controlled to release the medicament to at least part of the target tissue 310, so that the electrode needle 111 extending into the target tissue 310 can perform drug ablation on at least part of the surrounding target tissue 310, that is, the electrical ablation and the drug ablation are combined, and the ablation effect is improved; and the electrical ablation causes the adventitia of the target tissue 310 to form electroporation, which allows the agent to more easily enter the cells of the target tissue, which can greatly improve the ablation effect.
3. In the control method based on the ablation apparatus, the output of the first pulse sequence from the electrode needle 111 starts before the start point of the medicament releasing process of the electrode needle 111, and the output of the first pulse sequence from the electrode needle 111 ends after the end point of the medicament releasing process of the electrode needle 111. Therefore, the medicament can form cells which are electroporated into target tissues through the cell adventitia to the greatest extent, the ratio of the medicament entering the cells is improved, and the ablation effect inside the cells is improved.
4. In the control method based on the ablation device, at least one sub-agent releasing process is positioned between two adjacent electric pulses in the first pulse sequence, so that the alternating operation of each electric pulse in the first pulse sequence and each sub-agent releasing process in the agent releasing process can be favorably realized, and on one hand, the matching degree of electroporation and the sub-agent releasing process can be improved, namely, the cell outer membrane has effective electroporation when releasing agents every time, and the proportion of the agents entering cells is improved; on the other hand, the working state of the electrode needle 111 is favorably spaced, the influence between the medicament and the first pulse sequence is reduced, the respective effectiveness of electric ablation and medicament ablation is ensured, and the ablation effect is further improved.
5. In the control method based on the ablation apparatus, the output of the first pulse sequence from the electrode needle 111 starts before the start point of the medicament releasing process of the electrode needle 111, and the output of the first pulse sequence from the electrode needle 111 ends before the end point of the medicament releasing process of the electrode needle 111. Thus, the outer cell membrane can form effective electroporation in the process of releasing the medicament so as to facilitate the medicament to enter cells of the target tissue. That is, the ratio of the agent entering the cell can be increased, the ablation effect inside the cell can be improved, the time for outputting the first pulse sequence by the electrode needle 111 can be shortened, and the energy consumption can be saved.
6. In the ablation device-based control method, the at least one sub-release agent schedule is located after all electrical pulses in the first pulse train, which may facilitate continuous administration of the agent after electrical ablation. Specifically, irreversible electroporation is formed in the target tissue 310 under the action of ablation, and after continuous administration, the medicament can continue to enter cells through electroporation, so that the time of outputting the first pulse sequence by the electrode needle 111 can be shortened while the curative effect of drug ablation can be ensured, and the energy consumption can be saved.
7. In the control method based on the ablation device, the output of the first pulse sequence from the electrode needle 111 starts before the start point of the drug releasing process of the electrode needle 111, and the output of the first pulse sequence from the electrode needle 111 ends after the end point of the drug releasing process of the electrode needle 111. Therefore, the medicament can form cells which are electroporated into target tissues through the cell adventitia to the greatest extent, the ratio of the medicament entering the cells is improved, and the ablation effect inside the cells is improved.
8. The upper computer 120 in the ablation system 100 is in communication connection with the controller 113 in the ablation device 110, and the upper computer 120 can update the program or backup data of the ablation device 110, and can also remotely control the ablation device 110, thereby facilitating the function expansion of the ablation device 110.
Those of skill in the art will understand that various operations, methods, steps in the flow, measures, schemes discussed in this application can be alternated, modified, combined, or deleted. Further, other steps, measures, or schemes in various operations, methods, or flows that have been discussed in this application can be alternated, altered, rearranged, broken down, combined, or deleted. Further, steps, measures, schemes in the prior art having various operations, methods, procedures disclosed in the present application may also be alternated, modified, rearranged, decomposed, combined, or deleted.
In the description of the present application, it is to be understood that the terms "center", "upper", "lower", "front", "rear", "left", "right", "vertical", "horizontal", "top", "bottom", "inner", "outer", and the like indicate orientations or positional relationships based on those shown in the drawings, and are only for convenience in describing the present application and simplifying the description, but do not indicate or imply that the referred device or element must have a particular orientation, be constructed in a particular orientation, and be operated, and thus should not be construed as limiting the present application.
The terms "first", "second" and "first" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance or implicitly indicating the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include one or more of that feature. In the description of the present application, the meaning of "a plurality" is two or more unless otherwise specified.
In the description of the present application, it is to be noted that, unless otherwise explicitly specified or limited, the terms "mounted," "connected," and "connected" are to be construed broadly, e.g., as meaning either a fixed connection, a removable connection, or an integral connection; they may be connected directly or indirectly through intervening media, or they may be interconnected between two elements. The specific meaning of the above terms in this application will be understood to be a specific case for those of ordinary skill in the art.
In the description herein, particular features, structures, materials, or characteristics may be combined in any suitable manner in any one or more embodiments or examples.
It should be understood that, although the steps in the flowcharts of the figures are shown in order as indicated by the arrows, the steps are not necessarily performed in order as indicated by the arrows. The steps are not performed in the exact order shown and may be performed in other orders unless explicitly stated herein. Moreover, at least a portion of the steps in the flow chart of the figure may include multiple sub-steps or multiple stages, which are not necessarily performed at the same time, but may be performed at different times, and the order of execution is not necessarily sequential, but may be performed alternately or alternately with other steps or at least a portion of the sub-steps or stages of other steps.
The foregoing is only a few embodiments of the present application and it should be noted that those skilled in the art can make various improvements and modifications without departing from the principle of the present application, and that these improvements and modifications should also be considered as the protection scope of the present application.
Claims (10)
1. An ablation device, comprising:
an electrode needle for extending into a target tissue;
the pulse generating device is electrically connected with the electrode needle;
the controller is respectively in communication connection with the electrode needle and the pulse generating device and is used for controlling the electrode needle to release a medicament to at least part of target tissues so as to implement drug ablation on the target tissues around the electrode needle and controlling the pulse generating device to output an electric pulse sequence to the electrode needle; the sequence of electrical pulses includes a first sequence of pulses for performing irreversible electroporation ablation of at least a portion of the target tissue surrounding the electrode needle.
2. The ablation device of claim 1, wherein the electrode needle has a medicament chamber for connection to a medicament source, the peripheral wall of the electrode needle having a medicament release aperture in communication with the medicament chamber.
3. The ablation device of claim 1 or 2, wherein the controller comprises:
the electric pulse control module is used for controlling the pulse generating device to output a first pulse sequence to the electrode needle;
and the medicament releasing module is used for controlling the electrode needle to release the medicament to at least part of the target tissue at the first design time.
4. The ablation device of claim 3, wherein the agent releasing module is configured to control the electrode needle to release the agent to at least a portion of the target tissue at a first programmed time, and is further configured to: controlling the electrode needle to release the medicament after determining that the first pulse sequence is output through the electrode needle;
the electric pulse control module is used for controlling the pulse generating device to output a first pulse sequence to the electrode needle, and is specifically used for: and controlling the pulse generating device to stop outputting the first pulse sequence after all the medicament is determined to be released through the electrode needle.
5. The ablation device as defined in claim 4, wherein the medicament releasing module is configured to, after determining that the first pulse sequence is outputted through the electrode needle, control the electrode needle to release the medicament, and is specifically configured to:
after determining that at least one electric pulse in the first pulse sequence is output through the electrode needle, controlling the electrode needle to perform at least one sub-medicament release process in at least two sub-medicament release processes;
and after determining that at least one other electric pulse in the first pulse sequence is output through the electrode needle, controlling the electrode needle to perform at least one other sub-release medicament process in at least two sub-release medicament processes.
6. The ablation device of claim 3, wherein the agent releasing module is configured to control the electrode needle to release the agent to at least a portion of the target tissue at a first programmed time, and is further configured to:
controlling the electrode needle to release the medicament after determining that the first pulse sequence is output through the electrode needle;
and controlling the electrode needle to stop releasing the medicament after determining that the electrode needle stops outputting the first pulse sequence.
7. The ablation device of claim 6, wherein the agent releasing module is configured to control the electrode needle to release the agent after determining that the first pulse sequence is started to be output through the electrode needle, and is specifically configured to:
and after determining that at least one electric pulse in the first pulse sequence is output through the electrode needle, controlling the electrode needle to perform at least one sub-medicament release process in at least two sub-medicament release processes.
8. The ablation device of claim 6 or 7, wherein the agent releasing module is configured to, after determining that the electrode needle stops outputting the first pulse sequence, control the electrode needle to stop releasing the agent, and specifically:
and after the electrode needle is determined to stop outputting the first pulse sequence, controlling the electrode needle to perform at least another sub-medicament release process in at least two sub-medicament release processes.
9. The ablation device as in claim 3, wherein the agent releasing module is configured to control the electrode needle to release the agent to at least a portion of the target tissue at a first programmed time, and is further configured to:
controlling the electrode needle to release the medicament when it is determined that the entire first pulse sequence is output through the electrode needle and a second design time has elapsed.
10. An ablation system, comprising: the ablation device of any one of claims 1-9, and a host computer;
the upper computer is in communication connection with a controller in the ablation device.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110031437.1A CN112869871B (en) | 2021-01-11 | 2021-01-11 | Ablation device, control method, device, system and storage medium thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110031437.1A CN112869871B (en) | 2021-01-11 | 2021-01-11 | Ablation device, control method, device, system and storage medium thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112869871A CN112869871A (en) | 2021-06-01 |
| CN112869871B true CN112869871B (en) | 2022-10-14 |
Family
ID=76046111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110031437.1A Active CN112869871B (en) | 2021-01-11 | 2021-01-11 | Ablation device, control method, device, system and storage medium thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112869871B (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12076071B2 (en) | 2020-08-14 | 2024-09-03 | Kardium Inc. | Systems and methods for treating tissue with pulsed field ablation |
| CN113229929A (en) * | 2021-06-18 | 2021-08-10 | 杭州维纳安可医疗科技有限责任公司 | Electrode needle, ablation equipment, ablation method, device and storage medium |
| CN113229931A (en) * | 2021-06-18 | 2021-08-10 | 杭州维纳安可医疗科技有限责任公司 | Electrode needle, ablation equipment, ablation method, device and storage medium |
| CN113229928B (en) * | 2021-06-18 | 2023-12-15 | 杭州维纳安可医疗科技有限责任公司 | Electrode needle, ablation equipment, ablation method, device and storage medium |
| CN113229930B (en) * | 2021-06-18 | 2023-09-22 | 杭州维纳安可医疗科技有限责任公司 | Electrode needle, ablation equipment, ablation method, device and storage medium |
| CN113663217A (en) * | 2021-08-19 | 2021-11-19 | 杭州维纳安可医疗科技有限责任公司 | Electric field generation system, control method and device for enhancing tumor treatment field effect |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6623457B1 (en) * | 1999-09-22 | 2003-09-23 | Becton, Dickinson And Company | Method and apparatus for the transdermal administration of a substance |
| CN101495056A (en) * | 2006-06-12 | 2009-07-29 | 京畿州海莱乌医院 | Electrode introducer device |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1953737A (en) * | 2004-05-03 | 2007-04-25 | 埃-皮尔制药公司 | Active drug delivery in the gastrointestinal tract |
| CN101888874B (en) * | 2007-10-11 | 2013-11-13 | 京畿州海莱乌医院 | An electroporation device for improved electrical field control |
| US9433752B2 (en) * | 2012-11-14 | 2016-09-06 | Biosense Webster (Israel) Ltd. | Catheter with flat beam deflection in tip |
| CN105769332B (en) * | 2016-02-22 | 2019-07-16 | 绵阳立德电子股份有限公司 | RF energy dispensing controller, RFA system and the method for realizing RF energy distribution control using the controller |
| CN209595886U (en) * | 2019-01-29 | 2019-11-08 | 深圳市人民医院 | For treating the electroporation operation device of glioma |
-
2021
- 2021-01-11 CN CN202110031437.1A patent/CN112869871B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6623457B1 (en) * | 1999-09-22 | 2003-09-23 | Becton, Dickinson And Company | Method and apparatus for the transdermal administration of a substance |
| CN101495056A (en) * | 2006-06-12 | 2009-07-29 | 京畿州海莱乌医院 | Electrode introducer device |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112869871A (en) | 2021-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112869871B (en) | Ablation device, control method, device, system and storage medium thereof | |
| CN112842516B (en) | Ablation device, control method, device, system and storage medium thereof | |
| US20220313346A1 (en) | Method and device for controlling output of radiofrequency ablation power, and radiofrequency ablation system | |
| US6185461B1 (en) | System and method for verification of recommended replacement time indication in an implantable cardiac stimulation device | |
| Weiss et al. | Chaos and the transition to ventricular fibrillation: a new approach to antiarrhythmic drug evaluation | |
| Göktepe et al. | Atrial and ventricular fibrillation: computational simulation of spiral waves in cardiac tissue | |
| US20240189014A1 (en) | Pulse Control Method And Apparatus, Ablation Device And System, and Storage Medium | |
| JP2015514550A (en) | Timing channel circuit for generating pulses in an implantable stimulation device | |
| CN112869872B (en) | Ablation device, control method, device, system and storage medium thereof | |
| CN112912134A (en) | Implantable medical device securely connected to external instrument | |
| JP2017538493A5 (en) | ||
| CN116458993B (en) | Pulse ablation control system | |
| CN103480092A (en) | Device and method for controlling ultrasonic energy output and ultrasonic therapy device | |
| CN113476742A (en) | System for inhibiting pathological cell division and control method thereof | |
| CN113229930B (en) | Electrode needle, ablation equipment, ablation method, device and storage medium | |
| US10881864B2 (en) | Methods and systems for generating stimulation waveforms for a neurostimulation therapy | |
| CN114430673A (en) | System and method for controlling laser pulse generation | |
| US8958875B2 (en) | Stimulation mode switching based on tissue impedance stability | |
| CN113229931A (en) | Electrode needle, ablation equipment, ablation method, device and storage medium | |
| CN113230537A (en) | Electric signal generating equipment capable of monitoring in real time, control method, device and system | |
| CN115068104A (en) | Pulse electric field ablation renal artery nerve control system | |
| CN104941068B (en) | Implantable medical device with clock and self-timing component | |
| CN112553190A (en) | Drug transmembrane delivery method and high repetition frequency bipolar pulse system | |
| CN202982961U (en) | Combined type therapeutic instrument | |
| CN113229928B (en) | Electrode needle, ablation equipment, ablation method, device and storage medium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210602 Address after: Room 101-106, 109 (1), building 8, No.20, kejiyuan Road, Qiantang New District, Hangzhou City, Zhejiang Province 310018 Applicant after: Hangzhou vena Anke Medical Technology Co.,Ltd. Address before: 310018 room a0101-21, building 2, 452, Baiyang street, Qiantang New District, Hangzhou City, Zhejiang Province Applicant before: Hangzhou viatech Medical Technology Co.,Ltd. |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |